Caffeoylalphaneoendorphin peptide derivative and use thereof as anti-itching and anti-atopic agents

Abstract

Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.

1 . A peptide derivative represented by the following Chemical Formula 1: 
       
         
           
           
               
               
           
         
         where, 
         R 1 , R 4 , and R 5  are independently hydrogen, hydroxy, C 1 -C 6  alkyl group, C 1 -C 6  alkoxy group, cyano, halo, or amino, respectively; 
         R 2  and R 3  are hydroxy; 
         n is 1; 
         L is either absent or a linking group; and 
         A is peptide or fragment thereof having the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (YGGFLRRIRPKLK). 
       
     
     
         2 - 7 . (canceled) 
     
     
         8 . The peptide derivative according to  claim 1 , further comprising at least one of a adjuvant, solution, suspension, turbid fluid, paste, gel, cream, powder, and spray. 
     
     
         9 . The peptide derivative according to  claim 8 , further comprising at least one of a stabilizer, solubilizer, vitamin, pigment, and flavoring. 
     
     
         10 . The peptide derivative according to  claim 8 , further comprising at least one of an animal oil, vegetable oil, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, and zinc oxide. 
     
     
         11 . The peptide derivative according to  claim 8 , further comprising at least one of a lactose, talc, silica, aluminum hydroxide, calcium silicate, and polyamide powder. 
     
     
         12 . The peptide derivative according to  claim 8 , further comprising a propellant. 
     
     
         13 . The peptide derivative according to  claim 12 , further comprising at least one of a chlorofluorohydrocarbon, propane, butene, and dimethylether. 
     
     
         14 . The peptide derivative according to  claim 8 , further comprising at least one of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol fatty acid ester, polyethylene glycol, and fatty acid of sorbitan. 
     
     
         15 . The peptide derivative according to  claim 8 , further comprising at least one of water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, microcrystal cellulose, aluminum metahydroxide, bentonite, agar, and tragacanth. 
     
     
         16 . The peptide derivative according to  claim 1 , further comprising at least one of a fat material, organic solvent, dissolvent, thickening agent, gelling agent, softener, antioxidant, suspension agent, stabilizer, foaming agent, flavoring agent, preserved agent, vitamin, blocker, moistening agent, essential oil, dye, pigment, hydrophilic activator, lipophilic activator, lipid vesicle, and adjuvant. 
     
     
         17 . The peptide derivative according to  claim 1 , further comprising a carrier present in an amount of about 1 wt % to about 99.99 wt %. 
     
     
         18 . The peptide derivative according to  claim 1 , wherein the carrier is present in the amount of about 90 wt % to about 99.99 wt %. 
     
     
         19 . A method comprising administering to a subject a caffeoyl peptide derivative represented by the Chemical Formula 1: 
       
         
           
           
               
               
           
         
         where, 
         R 1 , R 4 , and R 5  are independently hydrogen, hydroxy, C 1 -C 6  alkyl group, C 1 -C 6  alkoxy group, cyano, halo, or amino, respectively; 
         R 2  and R 3  are hydroxy; 
         n is 1; 
         L is either absent or a linking group; and 
         A is peptide or fragment thereof having the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (YGGFLRRIRPKLK). 
       
     
     
         20 . The method according to  claim 19 , wherein the administering comprises at least one of a topical, oral, and intravenous administration. 
     
     
         21 . The method according to  claim 19 , wherein the administering is to treat or prevent an atopic dermatitis. 
     
     
         22 . The method according to  claim 19 , wherein the administering is to prevent or alleviate skin itching. 
     
     
         23 . The method according to  claim 19 , wherein the administering is to suppress or reduce expression of an inflammatory factor. 
     
     
         24 . The method according to  claim 23 , wherein the inflammatory factor comprises at least one of IL-4, IL-5, IL-13, IL-31, IL-10, TNFα, and IL-17. 
     
     
         25 . The method according to  claim 19 , wherein the administering further comprises administering at least one of a adjuvant, solution, suspension, turbid fluid, paste, gel, cream, powder, and spray. 
     
     
         26 . The method according to  claim 19 , wherein the peptide derivative is administered in a cosmetic composition.